Common misconceptions about thyroid function
Thyroid function is often misunderstood. This article examines common misconceptions and the research studies that address them, including trials on vitamin E, enclomiphene, growth hormone analogs, and more.
Thyroid function refers to the endocrine system's regulation of metabolism, growth, and development through the synthesis and secretion of thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3). These hormones are produced by the thyroid gland, a butterfly-shaped organ located in the neck, under the control of thyroid-stimulating hormone (TSH) from the anterior pituitary. The hypothalamic-pituitary-thyroid (HPT) axis maintains circulating thyroid hormone levels within a narrow range via negative feedback. Common misconceptions about thyroid function include the belief that thyroid disorders are rare, that they only affect women, that thyroid function is independent of other endocrine axes, and that treatment with levothyroxine fully restores metabolic health. Research studies continue to explore these assumptions.
The work centres on the HPT axis and its interactions with other endocrine pathways, including the hypothalamic-pituitary-gonadal (HPG) axis and the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis, as well as the role of oxidative stress and inflammation in thyroid autoimmunity.
Research Studies
Vitamin E and oxidative stress in levothyroxine-treated hypothyroidism
A clinical trial is investigating whether vitamin E supplementation as an adjunct to levothyroxine therapy can reduce oxidative stress, improve antioxidant defence mechanisms, and favourably influence thyroid hormone status in patients with hypothyroidism. The study aims to establish an evidence-based framework for integrating targeted antioxidant therapies into standard hypothyroid management strategies [1]. This research addresses the misconception that levothyroxine alone fully resolves all aspects of hypothyroidism, particularly oxidative stress.
Enclomiphene and cardiovascular safety in secondary male hypogonadism
Enclomiphene citrate is increasingly prescribed off-label for secondary male hypogonadism, but its cardiovascular safety profile remains poorly characterised. A case report described a 46-year-old man with a history of mitral valve repair and chronic immune thrombocytopenia who developed atrial flutter shortly after inadvertently increasing his enclomiphene dose from 25 mg to 50 mg daily. Laboratory evaluation showed normal thyroid function, cardiac biomarkers, and electrolytes, with chronic thrombocytopenia (platelet count 36 × 10⁹/L). Transthoracic echocardiography revealed preserved left ventricular systolic function with mild aortic regurgitation [2]. This case highlights the need to consider cardiovascular effects of hormonal agents, even when thyroid function is normal.
Long-acting growth hormone analogs and hypothalamic-pituitary axes
A real-world study examined hormonal changes in children with isolated growth hormone deficiency (GHD) starting long-acting growth hormone (LAGH) analog somatrogon or switching from daily recombinant human growth hormone (rhGH) to the same weekly analogue. The study included 33 children (n=16 starting somatrogon, n=17 switching) and assessed baseline and follow-up changes in other pituitary axes, including thyroid function [3]. This research challenges the misconception that growth hormone therapy affects only linear growth, without influencing other endocrine axes.
Biomarkers and pharmacogenomics for precision depression therapy
A randomized controlled trial is evaluating pharmacogenomics-guided therapy versus conventional treatment in 220 patients with major depressive disorder (MDD), with a 12-week follow-up. The study includes a matched healthy control cohort for cross-sectional biomarker comparisons [4]. While not focused on thyroid function per se, this trial underscores the broader principle that inter-individual variability in drug response can be informed by genetic and biomarker data, a concept applicable to thyroid disorders.
Obesity registry and thyroid function panel
A large real-world registry study will enroll 10,000 patients with obesity across approximately 50 medical institutions in China. Baseline assessments include a thyroid function panel (3 items) along with demographic, laboratory, and imaging data. Patients receive weight-loss therapy in routine clinical practice, with data on adverse events and therapeutic changes collected centrally [5]. This study addresses the misconception that thyroid function is unrelated to obesity and metabolic health.
Soluble α-Klotho-FGF23 axis in Hashimoto's thyroiditis
A prospective case-control study is comparing serum soluble α-Klotho and fibroblast growth factor 23 (FGF23) levels between adults with Hashimoto's thyroiditis and age- and sex-matched healthy controls. The study investigates associations with thyroid function parameters, inflammatory markers, and mineral metabolism [6]. This research challenges the misconception that Hashimoto's thyroiditis is solely a thyroid hormone disorder, highlighting its systemic inflammatory and mineral metabolism components.
Luteinizing hormone, hCG, and endocrine interactions
A study is evaluating the roles of luteinizing hormone (LH) and human chorionic gonadotropin (hCG) in adult patients undergoing assessment for endocrine disorders. Recent research suggests these hormones may influence bone health, body weight, kidney function, thyroid function, and adrenal function, beyond their reproductive roles [7]. This addresses the misconception that reproductive hormones act in isolation from thyroid regulation.
Adipokines and metabolic parameters with hormone replacement in hypothyroidism
A prospective observational study is evaluating changes in serum adipokine levels (asprosin, adipolin, omentin-1, and visfatin) and metabolic parameters in newly diagnosed primary hypothyroid patients before and after 8 weeks of levothyroxine replacement therapy [8]. This research challenges the misconception that biochemical restoration of thyroid hormone levels fully reflects metabolic improvement.
Comparison of thyroid function across studies
| Study | Population | Thyroid-related focus |
|---|---|---|
| Vitamin E add-on therapy [1] | Levothyroxine-treated hypothyroidism | Oxidative stress, antioxidant defence, thyroid hormone status |
| Enclomiphene case report [2] | 46-year-old man with secondary hypogonadism | Thyroid function normal; atrial flutter after dose escalation |
| LAGH real-world study [3] | Children with isolated GHD | Changes in other pituitary axes, including thyroid |
| Obesity registry [5] | 10,000 patients with obesity | Thyroid function panel as part of baseline assessment |
| Hashimoto's thyroiditis study [6] | Adults with Hashimoto's thyroiditis vs. controls | Soluble α-Klotho-FGF23 axis, inflammation, thyroid function |
| LH/hCG study [7] | Adults with endocrine disorders | Potential influence on thyroid function |
| Adipokine study [8] | Newly diagnosed primary hypothyroidism | Adipokines and metabolic parameters after levothyroxine |
If you are reading this for personal health reasons
The materials and information discussed here are sold for laboratory research purposes only. We do not provide dosing, medical guidance, or treatment recommendations. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Vitamin E Add-On Therapy, Thyroid Function & Oxidative Stress in Levothyroxine-Treated Hypothyroidism
- [2] Newly Detected Atrial Flutter After Enclomiphene Dose Escalation in a Patient With Prior Mitral Valve Repair and Chronic Immune Thrombocytopenia: A Case Report
- [3] Influence of long-acting growth hormone analogs on other hypothalamic-pituitary axes: a real-world study
- [4] Biomarkers and Pharmacogenomics for Precision Depression Therapy
- [5] Chinese, Overweight or Obesity, Real-World Registry Study
- [6] Dysregulation of the Soluble α-Klotho-FGF23 Axis in Hashimoto's Thyroiditis: A Case-Control Study
- [7] Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine Disorders
- [8] Serum Adipokines and Metabolic Parameters With Hormone Replacement in Newly Diagnosed Hypothyroidism